Chartampilas Evangelos, Rafailidis Vasileios, Georgopoulou Vivian, Kalarakis Georgios, Hatzidakis Adam, Prassopoulos Panos
Radiology Department, AHEPA University Hospital, Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Radiology Department, Ippokratio General Hospital of Thessaloniki, 54642 Thessaloniki, Greece.
Cancers (Basel). 2022 Aug 18;14(16):3997. doi: 10.3390/cancers14163997.
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer related death worldwide. Radiology has traditionally played a central role in HCC management, ranging from screening of high-risk patients to non-invasive diagnosis, as well as the evaluation of treatment response and post-treatment follow-up. From liver ultrasonography with or without contrast to dynamic multiple phased CT and dynamic MRI with diffusion protocols, great progress has been achieved in the last decade. Throughout the last few years, pathological, biological, genetic, and immune-chemical analyses have revealed several tumoral subtypes with diverse biological behavior, highlighting the need for the re-evaluation of established radiological methods. Considering these changes, novel methods that provide functional and quantitative parameters in addition to morphological information are increasingly incorporated into modern diagnostic protocols for HCC. In this way, differential diagnosis became even more challenging throughout the last few years. Use of liver specific contrast agents, as well as CT/MRI perfusion techniques, seem to not only allow earlier detection and more accurate characterization of HCC lesions, but also make it possible to predict response to treatment and survival. Nevertheless, several limitations and technical considerations still exist. This review will describe and discuss all these imaging modalities and their advances in the imaging of HCC lesions in cirrhotic and non-cirrhotic livers. Sensitivity and specificity rates, method limitations, and technical considerations will be discussed.
肝细胞癌(HCC)是全球癌症相关死亡的第四大主要原因。传统上,放射学在HCC的管理中发挥着核心作用,涵盖从高危患者的筛查到非侵入性诊断,以及治疗反应评估和治疗后随访。从有无对比剂的肝脏超声检查到动态多期CT以及采用扩散协议的动态MRI,在过去十年中已经取得了巨大进展。在过去几年中,病理、生物学、遗传学和免疫化学分析揭示了几种具有不同生物学行为的肿瘤亚型,凸显了重新评估既定放射学方法的必要性。考虑到这些变化,除形态学信息外还能提供功能和定量参数的新方法越来越多地被纳入现代HCC诊断方案中。这样一来,在过去几年中鉴别诊断变得更具挑战性。使用肝脏特异性对比剂以及CT/MRI灌注技术,似乎不仅能更早地检测出HCC病变并更准确地表征其特征,还能预测治疗反应和生存期。然而,仍然存在一些局限性和技术考量。本综述将描述和讨论所有这些成像方式及其在肝硬化和非肝硬化肝脏中HCC病变成像方面的进展。还将讨论敏感性和特异性率、方法局限性以及技术考量。